The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

rapamycin    

Synonyms: AGN-PC-00IKSQ, KBio1_001880, DivK1c_006936, HMS3265I15, HMS3265I16, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of rapamycin

 

Associations of rapamycin with other chemical compounds

 

Gene context of rapamycin

References

  1. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Lebbé, C., Euvrard, S., Barrou, B., Pouteil-Noble, C., Garnier, J.L., Glotz, D., Legendre, C., Francès, C. Am. J. Transplant. (2006) [Pubmed]
  2. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Granville, C.A., Warfel, N., Tsurutani, J., Hollander, M.C., Robertson, M., Fox, S.D., Veenstra, T.D., Issaq, H.J., Linnoila, R.I., Dennis, P.A. Clin. Cancer Res. (2007) [Pubmed]
  3. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Wu, Q., Kiguchi, K., Kawamoto, T., Ajiki, T., Traag, J., Carbajal, S., Ruffino, L., Thames, H., Wistuba, I., Thomas, M., Vasquez, K.M., DiGiovanni, J. Cancer Res. (2007) [Pubmed]
  4. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Huynh, H., Chow, P.K., Palanisamy, N., Salto-Tellez, M., Goh, B.C., Lee, C.K., Somani, A., Lee, H.S., Kalpana, R., Yu, K., Tan, P.H., Wu, J., Soong, R., Lee, M.H., Hor, H., Soo, K.C., Toh, H.C., Tan, P. J. Hepatol. (2008) [Pubmed]
  5. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Wei, C., Amos, C.I., Zhang, N., Wang, X., Rashid, A., Walker, C.L., Behringer, R.R., Frazier, M.L. Clin. Cancer Res. (2008) [Pubmed]
  6. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Su, T.I., Khanna, D., Furst, D.E., Danovitch, G., Burger, C., Maranian, P., Clements, P.J. Arthritis Rheum. (2009) [Pubmed]
  7. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Armstrong, A.J., Netto, G.J., Rudek, M.A., Halabi, S., Wood, D.P., Creel, P.A., Mundy, K., Davis, S.L., Wang, T., Albadine, R., Schultz, L., Partin, A.W., Jimeno, A., Fedor, H., Febbo, P.G., George, D.J., Gurganus, R., De Marzo, A.M., Carducci, M.A. Clin. Cancer Res. (2010) [Pubmed]
  8. Fighting neurodegeneration with rapamycin: mechanistic insights. Bové, J., Martínez-Vicente, M., Vila, M. Nat. Rev. Neurosci. (2011) [Pubmed]
  9. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Marty, F.M., Bryar, J., Browne, S.K., Schwarzberg, T., Ho, V.T., Bassett, I.V., Koreth, J., Alyea, E.P., Soiffer, R.J., Cutler, C.S., Antin, J.H., Baden, L.R. Blood (2007) [Pubmed]
  10. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Wang, Z., Zhou, J., Fan, J., Qiu, S.J., Yu, Y., Huang, X.W., Tang, Z.Y. Clin. Cancer Res. (2008) [Pubmed]
  11. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Moreno, A., Akcakanat, A., Munsell, M.F., Soni, A., Yao, J.C., Meric-Bernstam, F. Endocr. Relat. Cancer (2008) [Pubmed]
  12. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Wei, L.H., Su, H., Hildebrandt, I.J., Phelps, M.E., Czernin, J., Weber, W.A. Clin. Cancer Res. (2008) [Pubmed]
  13. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Verheul, H.M., Salumbides, B., Van Erp, K., Hammers, H., Qian, D.Z., Sanni, T., Atadja, P., Pili, R. Clin. Cancer Res. (2008) [Pubmed]
  14. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Pencreach, E., Guérin, E., Nicolet, C., Lelong-Rebel, I., Voegeli, A.C., Oudet, P., Larsen, A.K., Gaub, M.P., Guenot, D. Clin. Cancer Res. (2009) [Pubmed]
  15. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Kim, K.W., Moretti, L., Mitchell, L.R., Jung, D.K., Lu, B. Clin. Cancer Res. (2009) [Pubmed]
  16. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Gangadhar, T.C., Cohen, E.E., Wu, K., Janisch, L., Geary, D., Kocherginsky, M., House, L.K., Ramirez, J., Undevia, S.D., Maitland, M.L., Fleming, G.F., Ratain, M.J. Clin. Cancer Res. (2011) [Pubmed]
  17. The effect of sirolimus therapy on vaccine responses in transplant recipients. Willcocks, L.C., Chaudhry, A.N., Smith, J.C., Ojha, S., Doffinger, R., Watson, C.J., Smith, K.G. Am. J. Transplant. (2007) [Pubmed]
  18. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. Martin, K.A., Merenick, B.L., Ding, M., Fetalvero, K.M., Rzucidlo, E.M., Kozul, C.D., Brown, D.J., Chiu, H.Y., Shyu, M., Drapeau, B.L., Wagner, R.J., Powell, R.J. J. Biol. Chem. (2007) [Pubmed]
  19. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Nguyen, M., Huan-Tu, G., Gonzalez-Edick, M., Rivera, V.M., Clackson, T., Jooss, K.U., Harding, T.C. Mol. Ther. (2007) [Pubmed]
 
WikiGenes - Universities